Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Regression Models and Life-Tables

1992 • 27,454 citations

Regression Models and Life-Tables

1972 • 27,145 citations

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples

1977 • 8,468 citations

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2005 • 7,244 citations

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

1988 • 4,727 citations

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

2004 • 1,746 citations

A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

2005 • 1,530 citations

Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

2005 • 1,131 citations

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

2005 • 1,084 citations

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

2004 • 1,051 citations

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

2005 • 871 citations

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

2003 • 856 citations

Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial

2005 • 442 citations

Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen☆, ☆, ☆☆☆Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

2004 • 174 citations

Exact inference for categorical data: recent advances and continuing controversies

2001 • 152 citations

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

2006 • 137 citations

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?

2006 • 62 citations